Prognostic impact of concurrent radiographic progression at PSA-defined transition to castration resistance in de novo metastatic castration-sensitive prostate cancer
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Radiographic progression (rPD) at castration-resistant prostate cancer (CRPC) diagnosis remains poorly characterized in real-world settings. We assessed its prognostic impact and the clinical features of patients with rPD in real-world de novo metastatic castration-sensitive prostate cancer (mCSPC). Methods We retrospectively analyzed 330 patients with de novo mCSPC who progressed to CRPC from two multi-institutional cohorts: a conventional androgen deprivation therapy or combined androgen blockade (ADT/CAB) cohort ( n = 272) and an upfront intensification cohort ( n = 58). At CRPC diagnosis, patients were categorized as having prostate-specific antigen (PSA)-only progression or PSA + rPD. Post-CRPC overall survival (OS) was evaluated using Kaplan–Meier and Cox proportional hazards models, while rPD-associated characteristics were examined using logistic regression. Results Across both cohorts, patients with PSA + rPD had significantly shorter post-CRPC OS than those with PSA-only progression (ADT/CAB: 21 vs. 44 months, P < 0.001; upfront: 14 vs. 24 months, P = 0.008). Univariate Cox regression confirmed the adverse prognostic impact of rPD (hazard ratios 2.25 [95% CI 1.53–3.29] and 2.49 [95% CI 1.22–5.07]). Lower baseline PSA was significantly associated with rPD in the upfront cohort (odds ratio [OR] 0.30, 95% CI 0.12–0.75, P = 0.010), with a non-significant trend in the ADT/CAB cohort (OR 0.71, 95% CI 0.47–1.06, P = 0.092). Conclusion Radiographic progression at CRPC transition predicts poor post-CRPC survival in real-world mCSPC patients, regardless of initial treatment. Lower baseline PSA may identify patients at increased risk of rPD, supporting careful radiographic monitoring at CRPC transition.
Authors: Takeru Fujimoto, Takayuki Sumiyoshi, Kei Mizuno, Takanari Kambe, Toshifumi Takahashi, Hiroshi Fujiwara, Masashi Kubota, Hiroaki Kawanishi, Noboru Shibasaki, Koji Yoshimura, Yoshiyuki Nagumo, Ryoma Kurahashi, Yu Miyazaki, Norihiko Masuda, Takuro Miyagawa, Yuki Makino, Yuki Kita, Kimihiko Masui, Shusuke Akamatsu, Takashi Kobayashi, Takayuki Goto
Institutions: Kyoto University, Himeji Medical Center, National Hospital Organization, Osaka Red Cross Hospital, Japanese Red Cross Society Wakayama Medical Center, Shizuoka City Hospital, Tenri Hospital, Kobe Medical Center, Kobe City Medical Center General Hospital, Shizuoka General Hospital, University of Tsukuba, Kumamoto University, Kobe City Nishi-Kobe Medical Center, Rakuwakai Otowa Hospital, Hamamatsu Rosai Hospital, Kitano Hospital, Nagoya University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7171214465
